AUS
NZ
UK
CA
USA
IND
Highlights
AstraZeneca's Wainzua nerve damage treatment has received a recommendation for approval from the European Medicines Agency (EMA).
The treatment, known as eplontersen, is already approved in the US for adults with hereditary transthyretin-mediated amyloidosis-related polyneuropathy (ATTRv-PN).
If approved by the European Commission, Wainzua will be the only self-administered monthly treatment available in the EU for this debilitating condition.
AstraZeneca (LSE:AZN) has announced that its treatment for nerve damage, Wainzua, has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This treatment, also referred to as eplontersen, is jointly developed with California-based biotech firm Ionis Pharmaceuticals. It has already been approved for use in the United States, targeting adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
ATTRv-PN is a progressive and debilitating disease that leads to peripheral nerve damage and significant motor disability, often resulting in a grim prognosis if left untreated. The CHMP's recommendation comes after a phase III clinical trial demonstrated that Wainzua consistently improved neuropathy impairment and quality of life in patients compared to a placebo group.
Ruud Dobber, executive vice president of AstraZeneca's BioPharmaceuticals Business unit, emphasized the urgency of timely diagnosis and the need for innovative therapies to help patients manage this potentially fatal condition. The approval of Wainzua would not only provide a new treatment option but also enable patients to self-administer the medication on a monthly basis, enhancing convenience and adherence to treatment.
If granted final approval by the European Commission, Wainzua will become the only available self-administered treatment in the EU specifically designed for ATTRv-PN. This advancement represents a significant step forward in the fight against this debilitating disease, potentially improving the quality of life for many patients across Europe.
